[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356628-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356628-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","synthetic-lethality-of-decitabine-plus-atr-inhibition-for-tp53-mutated-aml","Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML","","TP53 mutations occur in 10% to 15% of myeloid neoplasms and carry a poor prognosis, with limited and often incomplete responses to hypomethylating agents (HMAs) such as decitabine. This study shows that decitabine induces replication stress via reduced replication fork progression, single-strand DNA break accumulation, and activation of the ATR pathway, while TP53-mutated AML cells have impaired stress resolution. Combining decitabine with ATR inhibition yields selective synthetic lethality in TP53-mutated AML, linked in part to mitotic catastrophe. Synergy translates to reduced leukemia burden and prolonged survival in vivo mouse models, supporting TP53 loss as a therapeutic vulnerability.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/synthetic-lethality-of-decitabine-plus-atr-inhibition-for-tp53-mutated-aml/356628/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/synthetic-lethality-of-decitabine-plus-atr-inhibition-for-tp53-mutated-aml/356628.png","ImageObject",300,407,{"name":42,"@type":43},"Maya Linwood","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does decitabine affect TP53-mutated AML cells?","Question",{"text":63,"@type":64},"Decitabine induces replication stress characterized by reduced replication fork progression, single-strand DNA breaks, and ATR pathway activation. Resolution of this replication stress is impaired in TP53-mutated AML cells.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why does combining decitabine with ATR inhibition work?",{"text":68,"@type":64},"The combination causes selective synthetic lethality in TP53-mutated AML cells, attributed in part to induction of mitotic catastrophe. This synergy is not seen with azacitidine or comparable global hypomethylation conditions.",{"name":70,"@type":61,"acceptedAnswer":71},"Is the therapeutic effect supported by in vivo studies?",{"text":72,"@type":64},"Yes. Decitabine plus an ATR inhibitor reduces leukemia burden and prolongs survival in mouse models of TP53-mutated AML.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356628,1790192815,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},962084928432,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","REGULAR ARTICLE  \nSynthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML  \nJeremy T. Baeten, 1,* Sumedha Agashe,1,* Imene Tabet,1 Jack T. Wooldridge, 1 Amber Carter,1 Jamie N. Butler, 1 Christopher A. Miller, 1 Nicole Helton,1 Annabel Quinet,2, 3 Kimberly B. Johansson, 1, 4 Yichan Yang,1 Geoffrey L. Uy, 1 Alessandro Vindigni,1 and Daniel C. Link1 1 Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO; 2 Stabilit´e G´en´etique Cellules Souches et Radiations Unit, Institut de Biologie François Jacob, Commissariat `a l’Energie Atomique et aux Energies Alternatives, Universit´e Paris-Saclay, Fontenay-aux-Roses, France; 3 Stabilit´e G´en´etique Cellules Souches et Radiations Unit, Universit´e Paris Cit´e, INSERM, Fontenay-aux-Roses, France; and 4 Medical Scientist Training Program, Washington University School of Medicine, St. Louis, MO  \nKey Points  \n• TP53 is required for the efficient resolution of replication stress induced by decitabine.  \n• The combination of decitabine plus an ATR inhibitor results in synthetic killing of TP53-mutated AML cells.  \nTP53 mutations are found in 10% to 15% of myeloid neoplasms and are associated with a dismal prognosis. Although hypomethylating agents (HMAs), such as decitabine, are active in TP53-mutated myeloid neoplasms (TP53-MN), mutation clearance is rarely complete and nearly all patients relapse. Molecular determinants of response to HMAs in TP53-MN are poorly understood. Here, we show that decitabine induces replicative stress with decreased replication fork progression, induction of single-strand DNA breaks, and activation of the ataxia telangiectasia mutated–Rad3-related (ATR) pathway. Resolution of decitabine-induced replication stress is impaired in TP53-mutated acute myeloid leukemia (AML) cells, representing a potential therapeutic vulnerability. Indeed, the combination of decitabine and ATR inhibition (ATRi) induces synthetic lethality that is selective for TP53-AML and due, in part, to induction of mitotic catastrophe. Interestingly, this synergistic lethality was not observed with azacitidine or treatment with GSK3685032, a potent DNA methyltransferase 1 inhibitor, both of which produce a comparable level of global hypomethylation to decitabine. Treatment with decitabine and an ATR inhibitor reduces leukemia burden and prolongs survival in in vivo mouse models of TP53-mutated AML. Collectively, these findings show that TP53 loss generates a selective vulnerability to decitabine-induced replication stress, with the combination of ATRi and decitabine showing promise as a new therapeutic approach for TP53-MN.  \nIntroduction  \nMyeloid malignancies with mutations in the tumor suppressor gene TP53 account for 10% to 15% of cases of de novo acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and ~35% of cases of therapy-related myeloid neoplasms. Only ~25% of patients with TP53-mutated AML respond to standard induction therapy, and median survival is less than 1 year.1-6 TP53 mutations are associated with complex karyotype AML, which itself has a poor prognosis. However, several studies show that the presence of biallelic TP53 mutation is an adverse prognostic factor that outweighs other known variables, including complex karyotype.2,6 Even allogeneic hematopoietic cell transplantation has limited success in this ultra-high-risk subgroup of AML, with 3-year overall survivals of 10% or less.7,8 Likewise, TP53 mutations are associated with a poor overall survival in MDS (5-year overall survival of ~20%) .9  \nSubmitted 9 September 2025; accepted 14 January 2026; prepublished online on Blood Advances First Edition 29 January 2026; final version published online 6 April 2026. [https://doi.org/10.1182/bloodadvances.2025018369](https://doi.org/10.1182/bloodadvances.2025018369) .  \n*J.T.B. and S.A. contributed equally to this study.  \nOriginal data and protocols are available from author, Jeremy Baeten (baeten@wust","cbCaiva3sNufzVI8","https://ap.wps.com/l/cbCaiva3sNufzVI8","pdf",4469911,15,"English","# Key Points\n# Introduction\n# Decitabine mechanism and replication stress\n# ATR pathway involvement\n# Therapeutic implications","[{\"question\":\"How does decitabine affect TP53-mutated AML cells?\",\"answer\":\"Decitabine induces replication stress characterized by reduced replication fork progression, single-strand DNA breaks, and ATR pathway activation. Resolution of this replication stress is impaired in TP53-mutated AML cells.\"},{\"question\":\"Why does combining decitabine with ATR inhibition work?\",\"answer\":\"The combination causes selective synthetic lethality in TP53-mutated AML cells, attributed in part to induction of mitotic catastrophe. This synergy is not seen with azacitidine or comparable global hypomethylation conditions.\"},{\"question\":\"Is the therapeutic effect supported by in vivo studies?\",\"answer\":\"Yes. Decitabine plus an ATR inhibitor reduces leukemia burden and prolongs survival in mouse models of TP53-mutated AML.\"}]","Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML | PDF",1790126396,38,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/59b45e5126be61d7b287f575e034c608.webp",983,1296,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/04334380579cf628ce5f064a118a8e90.webp",982,1294,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3c276a6b0fc3c25f28eaedd6e619c962.webp",981,1293,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3c85a046a6dfb1268c8ca36a73031677.webp",980,1292]